#ObesityMedicine #MetabolicHealth #GLP1 #ClinicalTrials #HealthcareInnovation #Semaglutide #Orforglipron #CagriSema #Retatrutide #Wegovy To view or add a comment, sign in : Eli Lilly and Company just released Phase 3 ATTAIN-MAINTAIN data on orforglipron, a once daily oral GLP-1 receptor agonist, and I think it speaks directly to one of the most painful realities my patients face: not losing weight, but it - Participants first completed 72 weeks on high-dose injectable semaglutide (Wegovy) or tirzepatide (Zepbound) in SURMOUNT-5, with very large average weight reductions
Integrating these tools in future research will enhance the molecular comprehension of autophagy dysregulation in transgenerational ovarian dysfunction
"Severity classification of GLP3-related adverse events: A multi-center study." Clinical Peptide Studies , 12(8), 445-462
While a small PDA is usually asymptomatic, a large PDA with significant left to right shunt may lead to CHF and eventually pulmonary hypertension
Skin biopsy was done from hyperpigmented skin on the thigh, which revealed excessive melanin pigmentation of the basal and supra-basal layers of the epidermis with melanophages in the dermis
